Emerald Health Pharmaceuticals to Present at the Biotech Showcase™ Annual Conference SAN DIEGO, Jan. 05, 2018 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), which is developing medications based on cannabinoid science, today announced that it will present at Biotech...

Emerald Health Pharmaceuticals Granted FDA Orphan Drug Designation for Systemic Scleroderma SAN DIEGO, Oct. 20, 2017 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), which is developing medications based on cannabinoid science, today announced that the U.S. Food and Drug...

Emerald Health Pharmaceuticals’ Scientific Team Leads Cannabinoid Research Showing Potential to Impact Neurodegenerative Diseases SAN DIEGO, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a development-stage company focused on treating life-threatening diseases through cannabinoid science, is...

Emerald Health Pharmaceuticals to Treat Life-Threatening Diseases with Novel Synthetic Cannabinoid-Derived Molecules SAN DIEGO, Sept. 14, 2017 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP) today announced its mission to discover, develop and commercialize novel synthetic cannabinoid-derivative drug...